2Dalmau J, Lancaster E, Martinez-Hemandez E, et al. Clinical experience and laboratory investigations in patients with antiNMDAR encephalitis. Lancet Neurol, 2011, 10: 63-74.
3Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDAreceptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol, 2008,7 : 1091-1098.
4Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol, 2005, 58: 594-604.
5Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroseientist, 2005, 11: 37-49.
6Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol, 2011, 69 : 292-302.
7Wandinger KP, Dalmau J, Borowski K, et al. Recombinant immunofluorescence assay for the detection of anti-glutamate receptor (type NMDA) antibodies in the differential diagnosis of autoimmune encephalopathies. 9th Symposium on Autoantibodies, Dresden, 2009.
8Hansotto Reibera, James B, Peter B. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci, 2001 : 101-122.
9Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D- aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol, 2009, 66 : 11-18.
10Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain, 2010, 133 : 1655-1667.
